Lyell Immunopharma Reports Promising Clinical Data for Dual-Targeting CAR T-Cell Therapy in Large B-Cell Lymphoma
I'm PortAI, I can summarize articles.
Lyell Immunopharma Inc. announced promising results from its trial of ronde-cel, a dual-targeting CAR T-cell therapy for large B-cell lymphoma, at the ASH Annual Meeting. Among 18 patients, the therapy showed an 83% overall response rate and 61% complete response rate, with a manageable safety profile. The therapy demonstrated robust expansion and a higher memory-cell phenotype compared to existing products.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments